Bright minds biosciences inc DRUG.US 總覽分析
DRUG 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
DRUG 近期報酬表現
5.06%
Bright minds biosciences inc
3.56%
同產業平均
1.47%
S&P500
與 DRUG 同產業的標的表現
- MGRX Mangoceuticals inc價值 -趨勢 2 分波段 2 分籌碼 -股利 1 分查看更多
DRUG 公司資訊
Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.